A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium
Lewis R. Silverman(Icahn School of Medicine at Mount Sinai), Richard Piekarz(Yeshiva University), Eric J. Feldman(The University of Texas MD Anderson Cancer Center), Vesna Najfeld, Maria R. Baer(University of Maryland, Baltimore), Erin P. Demakos(Tisch Hospital), Joseph A. Sparano(Tisch Cancer Institute), Rosalie Odchimar-Reissig(Icahn School of Medicine at Mount Sinai), Shyamala Navada(Geron (United States)), Amit Verma(Albert Einstein College of Medicine)
Cited by 27
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
|Journal of Clinical Oncology|2009|963
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830